Literature DB >> 18657899

Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell.

Xiaojun Yang1, Youcheng Zhang, Lingyi Zhang, Lin Zhang, Jie Mao.   

Abstract

The expression of alpha-fetoprotein (AFP), a tumor-associated antigen, is silenced in normal adult hepatocyte but reactivated in human hepatocellular carcinoma (HCC). To investigate the roles of AFP in the regulation of cell growth, we silenced AFP expression in the HCC cell line Huh7 by transfection of specific Stealth RNAi. After the transfection for 48 h, the expression of AFP gene was almost abolished, the cell proliferation was inhibited by 46.15%, and the number of cells undergoing early apoptosis was significantly increased to 63.93%. Inhibition of AFP expression also resulted in an increased in Bax/Bcl-2 ratio, the release of cytochrome c from mitochondria and activation of caspase-3. The results suggest that AFP may positively regulate cell proliferation by enhancing the apoptosis resistance via dysfunction of the p53/Bax/cytochrome c/caspase-3 signaling pathway in AFP-producing HCC cell line. As such, the knockdown of AFP gene should be further investigated in vivo as a novel approach to HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657899     DOI: 10.1016/j.canlet.2008.06.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.

Authors:  Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines.

Authors:  Brian I Carr; Ziqiu Wang; Meifung Wang; Gang Wei
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

3.  Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma.

Authors:  Wenna Shi; Lihui Su; Qianqian Li; Lidan Sun; Jing Lv; Jun Li; Baoquan Cheng
Journal:  Tumour Biol       Date:  2014-06-27

4.  Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer.

Authors:  Tiantian Wang; Jiancheng Yuan; Nenggui Feng; Yuchi Li; Zheguang Lin; Zhimao Jiang; Yaoting Gui
Journal:  Tumour Biol       Date:  2014-10

Review 5.  Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.

Authors:  Song He; Dechun Zhang; Fang Cheng; Fanghong Gong; Yanan Guo
Journal:  Mol Biol Rep       Date:  2009-01-01       Impact factor: 2.316

6.  Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.

Authors:  Han Kiat Ho; Boon Tin Chua; Winnie Wong; Kah Suan Lim; Vivian Teo; Hooi-Tin Ong; Xiao Chen; Wei Zhang; Kam M Hui; Mei Lin Go; Axel Ullrich
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

Review 7.  Immunotherapy of cancer in 2012.

Authors:  John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone
Journal:  CA Cancer J Clin       Date:  2012-05-10       Impact factor: 508.702

8.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  EPS364, a Novel Deep-Sea Bacterial Exopolysaccharide, Inhibits Liver Cancer Cell Growth and Adhesion.

Authors:  Yun Wang; Ge Liu; Rui Liu; Maosheng Wei; Jinxiang Zhang; Chaomin Sun
Journal:  Mar Drugs       Date:  2021-03-22       Impact factor: 5.118

10.  Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis.

Authors:  Naota Taura; Sachiko Fukuda; Tatsuki Ichikawa; Hisamitsu Miyaaki; Hidetaka Shibata; Takuya Honda; Tohei Yamaguchi; Yoko Kubota; Shinjiro Uchida; Yasuhiro Kamo; Emi Yoshimura; Hajime Isomoto; Takehiro Matsumoto; Fuminao Takeshima; Takuya Tsutsumi; Shotaro Tsuruta; Kazuhiko Nakao
Journal:  Exp Ther Med       Date:  2012-09-17       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.